Andere talen Immunic, Inc.

Aandelen

IMUX

US4525EP1011

Beurs gesloten - Nasdaq Andere beurzen 22:00:00 26-04-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
1,22 ^USD	-3,17%		+3,39%	-18,67%

09/04	Transcript : Immunic, Inc. - Special Call
21/03	Immunic krijgt bericht van toelating voor een Amerikaans octrooi voor een specifieke polymorf van vidofludimus calcium	MT

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Immunic to Host MS R&D Day and Participate in Investor Conferences in April	04/04
Immunic Gets US Patent Notice of Allowance For Specific Polymorph of Vidofludimus Calcium	21/03
Immunic CMO discusses complexities of multiple sclerosis to mark MS Awareness Month	21/03
Immunic secures key patent, boosting MS drug exclusivity and global IP strategy	21/03
Immunic Receives Notice of Allowance for Composition-of-Matter Patent of a Specific Polymorph of Vidofludimus Calcium in the United States	20/03
Immunic to reveal promising MS treatment data in two poster presentations at ACTRIMS Forum 2024	08/03
Immunic to Participate in Investor and Scientific Conferences in March	07/03
Immunic Presents Data From Phase 2 CALLIPER and CALVID-1 Trials of Vidofludimus Calcium at the ACTRIMS Forum 2024	29/02
Immunic reports successful 2023 and prepares for key 2025 milestones	22/02
Immunic, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	22/02
Immunic, Inc. Reports Year End 2023 Financial Results and Provides Corporate Update	22/02
Immunic, Inc. to Announce Financial Results for the Year Ended December 31, 2023, and Provide Corporate Update	15/02
Immunic to Participate in Investor and Scientific Conferences in February	01/02
Immunic Launches 3-Tranche Private Placement of Up to $240 Million; Shares Rise	05/01
Wall Street Set to Open Lower as Monthly Jobs Data Much Stronger Than Expected	05/01
Investors Await Jobs Data as US Futures Trend Lower in Friday's Premarket	05/01
Top Premarket Gainers	05/01
Immunic, Inc. Announces Private Placement of up to $240 Million	05/01
Immunic Files $250 Million Mixed-Securities Shelf Registration	22/11
Immunic Receives Notice of Allowance From US Patent Office for Dosing Regimens for Treating Multiple Sclerosis	21/11

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Immunic, Inc.

Aandelen

IMUX

US4525EP1011

Andere talen

Filters